New study tracks daily life of leukemia patients on acalabrutinib
NCT ID NCT06548152
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study measures how people with chronic lymphocytic leukemia feel and function while taking acalabrutinib in everyday life. Researchers will look at quality-of-life scores from treatment start up to 12 months later. About 120 adults in France who are starting acalabrutinib for the first time will take part. The goal is to understand real-world well-being beyond what clinical trials usually capture.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site
RECRUITINGSaint-Affrique, France